Publicaciones en las que colabora con ONINTZA SAGREDO EZQUIOGA (25)

2023

  1. Disease-modifying effects of cannabidiol, β-caryophyllene and their combination in Syn1-Cre/Scn1aWT/A1783V mice, a preclinical model of Dravet syndrome

    Neuropharmacology, Vol. 237

2022

  1. Preclinical investigation of β-caryophyllene as a therapeutic agent in an experimental murine model of Dravet syndrome

    Neuropharmacology, Vol. 205

2021

  1. Chapter 2: Phytocannabinoids Versus Endocannabinoids. A Modern View of the Endocannabinoid System

    RSC Drug Discovery Series (Royal Society of Chemistry), pp. 10-47

  2. Neuropathological Characterization of a Dravet Syndrome Knock-In Mouse Model Useful for Investigating Cannabinoid Treatments

    Frontiers in Molecular Neuroscience, Vol. 13

2020

  1. Possible therapeutic applications of cannabis in the neuropsychopharmacology field

    European Neuropsychopharmacology, Vol. 36, pp. 217-234

2017

  1. Effects of a sativex-like combination of phytocannabinoids on disease progression in R6/2 mice, an experimental model of huntington’s disease

    International Journal of Molecular Sciences, Vol. 18, Núm. 4

2016

  1. A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease

    Journal of Neurology, Vol. 263, Núm. 7, pp. 1390-1400

  2. Analysis of endocannabinoid signaling elements and related proteins in lymphocytes of patients with Dravet syndrome

    Pharmacology Research and Perspectives, Vol. 4, Núm. 2

2014

  1. A restricted population of CB1 cannabinoid receptors with neuroprotective activity

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 111, Núm. 22, pp. 8257-8262

2013

  1. Cannabidiol for neurodegenerative disorders: Important new clinical applications for this phytocannabinoid?

    British Journal of Clinical Pharmacology, Vol. 75, Núm. 2, pp. 323-333

  2. Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy

    Journal of Alzheimer's Disease, Vol. 35, Núm. 3, pp. 525-539

  3. The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: A potential role of cyclooxygenase-2-dependent metabolism of 2-AG

    Cell Death and Disease, Vol. 4, Núm. 10

2012

  1. Cannabinoids: Novel medicines for the treatment of Huntington's disease

    Recent Patents on CNS Drug Discovery, Vol. 7, Núm. 1, pp. 41-48

  2. Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: Role of CB1 and CB2 receptors

    ACS Chemical Neuroscience

2011

  1. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease

    Brain, Vol. 134, Núm. 1, pp. 119-136

  2. Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease

    Journal of Neuroscience Research, Vol. 89, Núm. 9, pp. 1509-1518

2010

  1. The endocannabinoid system as a target for the treatment of neuronal damage

    Expert Opinion on Therapeutic Targets, Vol. 14, Núm. 4, pp. 387-404

2009

  1. Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease

    GLIA, Vol. 57, Núm. 11, pp. 1154-1167

  2. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity

    Brain, Vol. 132, Núm. 11, pp. 3152-3164

2008

  1. Role of CB2 receptors in neuroprotective effects of cannabinoids

    Molecular and Cellular Endocrinology, Vol. 286, Núm. 1-2 SUPPL. 1